one or more elements in the immune response underlying RA (2) .
In the general population, 30-60% of the risk of developing coronary artery disease (CAD) is estimated to be genetic (3) . Genome-wide association studies (GWAS) have identified and validated .100 singlenucleotide polymorphisms (SNPs) that are associated with CAD susceptibility. Moreover, the risk of CAD is proportional to the number of these SNPs inherited by an individual (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . These SNPs have been associated with an increased risk of CAD through diverse mechanisms, including effects on lipid metabolism, plaque stability, and acute MI. Still others act through unknown pathways, suggesting varying impacts of different alleles on the biology and pathophysiology of CVD. In particular, some SNPs focus attention on novel and intriguing mechanisms contributing to CAD, such as those mapping to the 53-kb region of chromosome 9p21.3, an area without classic genes that encodes an antisense noncoding RNA in the INK4 locus, designated ANRIL, or CDKN2B-AS1 (22) . Homozygosity for 9p21.3 risk alleles confers a population-attributable risk of 21% for CAD (23) . Similarly, pathways involving glycotransferase activity encoded at the ABO locus are considered to foster development of MI in the general population, acting on the stage of CAD pathogenesis after development of atherosclerosis (24) .
Coronary artery calcification (CAC) detected by computed tomography is a noninvasive validated measure of subclinical CAD in the general population (25) . Direct relationships have been established between CAC scores and histologic, intracoronary ultrasonic, and angiographic measures of coronary artery atherosclerosis and plaque burden on a vessel-by-vessel and segment-by-segment basis (26) . CAC has been shown to predict incident MI even after adjustment for other traditional cardiovascular risk factors (27) . Importantly, analogous to CAD, the presence of CAC is also a heritable trait (28) , and the frequency of CAC is significantly higher in individuals with a parental history of CAD (29) . In the general population, it is now recognized that many of these SNPs predominantly exert their influence during different stages of the biologic events that ultimately lead to the development of MI, including atherosclerosis, CAC, and CAD (24) , and the presence of CAC analogously has been linked to the SNPs associated with CAD across multiple genetic loci (5, 30) .
Compared with the general population, both the prevalence of higher CAC scores and their magnitude are significantly increased in RA (31) . Elevated CAC scores in RA patients have also been shown to independently predict cardiovascular events (32) . Accordingly, we sought to determine whether in the subset of RA patients with CAC, the frequency of the SNPs associated with CAD in the general population would also be significantly increased compared with the frequency in the subset of RA patients without CAC. If this were shown to be the case, the implication would be that the effect of RA is to enhance the risk of CAD by acting through established genetic pathways that lead to CAD in the general population, resulting in an increased number of RA patients with CAC having these susceptibility genes. Alternatively, if the frequencies of these alleles were not shown to be significantly increased among RA patients with CAC, it would suggest that an increased frequency of CAC in RA is a consequence of RA-associated immune-mediated mechanisms that act independently of the genetically determined proatherosclerotic pathways operating in the general population.
PATIENTS AND METHODS
Study participants and data collection. A total of 561 patients with RA from 3 different clinic-based cohorts (the Evaluation of Subclinical Cardiovascular disease And Predictors of Events in Rheumatoid Arthritis [ESCAPE-RA] cohort from Johns Hopkins University [31] , and 2 additional cohorts from the University of Pittsburgh and Vanderbilt University, respectively) were included in this study. All of the patients (men and women) had RA as diagnosed by a rheumatologist and fulfilled the American College of Rheumatology 1987 revised criteria for the classification of RA (33) . The ESCAPE-RA study has been described in detail previously and was initiated to study the prevalence, progression, and risk factors for subclinical CVD in RA. A total of 197 patients ages 45-80 years with a disease duration of .6 months were recruited from the Johns Hopkins Arthritis Center. The Pittsburgh cohort consisted of 195 patients recruited from the University of Pittsburgh Medical Center Arthritis Network outpatient practices. In the Pittsburgh cohort, only female patients ages $16 years with a disease duration of $2 years were included. In the Vanderbilt cohort (n 5 169), all patients were a minimum age of 18 years, and there were 2 groups of patients: those with a disease duration of ,5 years (early RA) and those with a disease duration of .10 years (established RA). In this cohort, patients were obtained from a registry of patients with early RA, were referred by local rheumatologists, or were recruited via advertisements. Details of the Pittsburgh and Vanderbilt cohorts have also been previously described (34, 35) . Each study was approved by the Institutional Review Board of the universities/hospitals associated with the 3 cohorts, and all subjects provided written informed consent prior to enrollment.
Assessments and CAC quantification. Age, sex, race/ ethnicity, and current and past smoking were assessed based on patient self-report. Eighty-nine percent of patients in the 3 cohorts were white. Patients completed a questionnaire regarding medication use and underwent an examination to assess anthropometric measures and blood pressure. Medical records were reviewed to ascertain the diagnosis and medication received. Current and past use of glucocorticoids and biologic and nonbiologic disease-modifying antirheumatic drug use was queried by detailed examiner-administered questionnaires. Disease activity was measured using the Disease Activity Score in 28 joints (DAS28) using the erythrocyte sedimentation rate or the C-reactive protein (CRP) level (36) , and the degree of disease-related disability was determined using the Health Assessment Questionnaire (37) . Metabolic syndrome was defined using the 2005 National Cholesterol Education Program Adult Treatment Panel III criteria.
Fasting plasma and serum samples were collected and frozen until the analysis of circulating lipids, glucose, insulin, high-sensitivity CRP, and homocysteine. Rheumatoid factor (RF) was assessed by nephelometry, with seropositivity defined as a level of $40 units. All patients underwent cardiac computerized tomography using methodology described previously (38) . CAC was quantitated using the Agatston method (39) . In addition to using the CAC Agatston score as a continuous variable, we also categorized CAC as .0 and .10 Agatston units and the 75th and 90th percentiles, adjusted for age, sex, and race/ethnicity, as previously described (40) .
Genotyping, imputation, and genetic risk score calculation. We identified SNPs of interest from GWAS published until 2014 in which the phenotypes studied were MI, angiographically defined CAD, and CAC, which we refer to collectively as "CAD," and in which the association between a SNP and CAD exceeded a genome-wide association threshold (P , 5 3 10 8 ). We identified 100 CAD-related disease SNPs in the literature (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) SNPs) designed to perform both deep replication of major autoimmune and inflammatory diseases, and fine-mapping of established significant loci identified in GWAS (41) . Because some CAD SNPs in the GWAS were identified using alternative chips, such as the Metabochip (42), with a different selection of SNPs that are not present on the Immunochip, it was necessary to impute these untyped SNPs using Impute2 software (43) after being "pre-phased" using SHAPEIT (44) . SNPs with low imputation quality, a minor allele frequency of ,1%, or a HardyWeinberg equilibrium value of ,0.001 were excluded.
Of the 100 selected SNPs, 9 were neither able to be genotyped nor successfully imputed (rs17114036, rs6783981, rs1878406, rs273909, rs12205331, rs9268402, rs3184504, rs2895811, and rs17228213). A multilocus genetic risk score was constructed, as previously described using Plink 1.07 software (45) , for each individual by summing the number of CAD alleles (0, 1, or 2) for each of the 86 SNPs, weighted by their estimated effect sizes (OR) (rs6783981, rs2026458, rs10811647, rs17676451, rs3809346, and rs8001186 were not included in the genetic risk calculation because OR information was not available). Missing genotype values in the genetic risk score calculation were imputed with the cohort-specific averages of risk allele frequencies. Supplementary Table 1 shows the specific weights of the SNPs.
Statistical analysis. The hypothesis to be tested in this study design was that in the subset of RA patients with CAC, the frequency of the SNPs known, a priori from the literature, to be associated with CAD in the general population would be significantly increased in the subset of RA patients with CAC, versus their frequency in those RA patients without CAC. Accordingly, the correction for multiple comparisons required in a study with a posteriori hypotheses is not appropriate in this study design. In terms of study power, on the basis of previously published findings (46), we assumed that smoking, hypertension, and diabetes are associated with ;50% of the risk of an acute MI. In a European cohort (47), a genetic risk score created from 3 SNPs that have been credibly associated with CAC explained 2.4% of the variation in CAC, and a 45-SNP genetic risk score constructed from CADassociated SNPs explained an additional 4%. Proceeding with these conservative assumptions, in a multivariable regression model with an alpha level of 0.05 and a beta level of 0.10, and assuming a coefficient of determination of 50% and that this would increase to 52% when adding genetic risk score to the model, we estimated that we would need to enroll 425 subjects.
The distributions of all variables were examined. Means and SDs were calculated for all normally distributed continuous variables, and medians and interquartile ranges (IQRs) were calculated for continuous variables that were not normally distributed. For categorical variables, counts and percentages were calculated. CAC scores were modeled as the log of the CAC score plus 1, in order to account for scores of zero (Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.39862/abstract). CAC Agatston units are expressed as the median (IQR), and the Mann-Whitney U test was used to test for the significance of differences in CAC Agatston units between allele groups. Supplementary Table 2 shows the comparison of effect allele homozygous versus heterozygous allele status, and the comparison of the effect allele versus the noneffect allele. Similarly, logistic regression analysis adjusted for traditional cardiovascular risk factors (age, sex, diabetes, hypertension, dyslipidemia, and smoking) was also used to study the relationship of homozygous against heterozygous, or the relationship between the effect allele and the non-affect allele, with CAC expressed as ,0 and ,10 units higher than the 75th and 90th percentiles. This association analysis was performed using SNPTEST, which can account for some imputation uncertainty (48) (see Supplementary Table 2 ).
Linear trends for the association of the genetic risk score and CAC were tested using linear regression with orthogonal polynomial contrasts. To assess the relationship between CAC and the genetic risk score and the DAS28, 3 models were constructed: model 1 (adjusted for age and sex), model 2 (adjusted for model 1 plus traditional cardiovascular risk factors, e.g., diabetes, hypertension, smoking, and dyslipemia), and model 3 (constructed by adding the genetic risk score to both models 1 and 2). All statistical calculations were performed using SPSS software, version 21 (IBM). For all tests, a 2-tailed alpha value of 0.05 was considered significant.
RESULTS
Demographic, laboratory, and clinical characteristics. The clinical characteristics of the patients in the 3 cohorts are shown in Table 1 . The mean 6 SD age across the 3 cohorts was 57.6 6 10.5 years, 77% of the patients were women, and 89% of the patients were white. Cardiovascular comorbidity was not different between the groups except for a higher prevalence of hypertension, current smoking, and aspirin intake in the Vanderbilt cohort, in which patients with previously known CVD were allowed to enroll. There were no differences between cohorts regarding the CAC Agatston score. The median CAC Agatston score was 3.12 (IQR 0-134.35) in the 3 cohorts, and 35% and 21% of the patients had a CAC Agatston score higher than the 75th percentile and 90th percentile, respectively. The duration of RA disease was 10 years (IQR 3-20), 44% of the patients were receiving corticosteroid treatment, 32% were receiving antitumor necrosis factor therapy, and 65% were seropositive for RF. CAD-related SNPs in relation to RA CAC. Table  2 and Supplementary Table 2 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.39862/abstract) show the relationship between the 91 SNPs related to CAD in the general population and the presence of CAC in the RA cohort. Eighty-six of these SNPs did not exhibit any positive association with CAC in the RA cohort, considering either the affected versus the non-affected allele in homozygous or heterozygous inheritance with the CAC Agatston score as a continuous variable or in the association analysis using CAC categorizations. Only rs646776 (CELSR2), rs602633 (PSCR1), rs579459 (ABO), rs501120 (CXCL12), and rs17676451 (HAL) showed any positive relationship with CAC in $1 of the analyses. The rs579459 (ABO) and rs17676451 (HAL) genotypes exhibited the most consistent association between genotype and CAC Agatston units, with a significant increase in the frequency of the effect alleles in both homozygous and heterozygous genotype distributions; however, in the case of ABO, CAC categorizations, although demonstrating trends toward significance, were not significantly associated. The positive associations for the other 3 SNPs were much less consistent, e.g., for rs501120 (CXCL12) there was no association between the homozygous or heterozygous genotype distribution and CAC Agatston units; however, in heterozygotes there was a positive association with effect allele A in the CAC .10 Agatston unit category (OR 1.96 [95% confidence interval (95% CI)] 1.13, 3.41), although there was no association between any of the CAC categories and the homozygous AA genotype, which would be expected to be more sensitive (see Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.39862/abstract).
Notably, none of the group of 12 SNPs mapping in the 53-kb region of chromosome 9p21.3 encoding ANRIL, which are among the strongest predictors of CAD in the general population, exhibited any association with CAD. Moreover, in the instance of PHACTR1, which also is strongly positively associated with the risk of CAD in the general population, 3 SNPs (rs9369640, rs12526453, and rs1332844) consistently showed a limited and incomplete protective relationship with CAC; e.g., in the case of rs1332844, the P values for a homozygous or heterozygous mode of inheritance were 0.01 and 0.08, respectively. Additionally, COL4A2 (rs9515203) and LDLR (rs2228671) were negatively Number of homozygous SNPs in relation to RA CAC. When the association between the CAD-related SNPS and CAC was studied in the nonweighted and weighted set of SNPs, no significant association was observed. In particular, an increase in the number of both homozygous and heterozygous CVD-related SNPs was not significantly associated with an increase in log(CAC) Agatston units ( Figure 1A) . Correspondingly, CAC categories of .0 and .10 units and .75th and .90 percentiles did not exhibit an increased frequency of homozygous or heterozygous SNPs ( Figure 1B) .
Additionally, when CAD-related SNPs were weighted by their effect sizes, the resulting genetic risk score was not significantly associated with CAC. Furthermore, trend analysis showed no relationship between the genetic risk score and the log of the Agatston units (P 5 0.93) ( Figure 1C) .
Genetic risk score, disease activity, and CAC. Table 3 shows the relationship between CAC and the genetic risk score or disease activity through the value of the beta coefficient, which reflects the change in the genetic risk score as a function of the change in CAC categorizations. All of the categorizations of CAC were associated with a higher DAS28 after adjustment for age and sex. When this analysis was performed with adjustment for traditional cardiovascular risk factors such as diabetes, dyslipidemia, hypertension, and smoking, this relationship was maintained in patients in the . Similarly, the relationship between CAC and the DAS28 was not modified when the analysis was adjusted for the genetic risk score (model 3). In this regard, when we evaluated the association between the CAC .90th percentile category and the DAS28 for the contribution of the genetic risk score, the statistically significant association (b coefficient 0.42 [95% CI 0.04, 0.81], P 5 0.03) between CAC and the DAS28 was maintained in this set of patients and was not modified by the genetic risk score.
DISCUSSION
The central finding of our study is that RA patients with CAC, compared with those without CAC, do not exhibit an increased frequency of the multiple CADspecific SNPs found at increased frequency among individuals in the general population who have CAD. This finding suggests that CAC in RA does not develop through the concerted action of the same genes and their related pathways implicated in the development of CAD in the general population. The lack of contribution of these proatherosclerotic genes implies that RA itself should be considered an independent cardiovascular risk factor. Accordingly, we suggest that some factor in the RA immune response primarily contributes to the increased prevalence and incidence of CVD in RA through pathways distinct from the proatherosclerotic pathways that operate in the general population to cause CAD. CVD has an estimated heritability in the general population of 30-60%, and GWAS have identified SNPs at several genomic regions associated with atherosclerosis, CAD, and progression to MI 49) . However, the role of these CAD-associated SNPs known to be related to CVD in the general population has not been previously explored in RA patients. In this study, we used CAC as a complex cardiovascular trait related to CAD. The use of CAC as a validated CAD equivalent is supported by its ability to predict incident coronary heart disease even after adjustment for traditional cardiovascular risk factors (27) .
Because each individual genetic variant specified by a SNP explains a small fraction of the variation in a complex trait and thus has limited predictive capacity for disease risk (50), we also constructed a weighted genetic risk score with all of the CAD-related SNPs. The genetic risk score is one of the most promising ways to aggregate multiple sets of SNP results into a single genetic predictor and in previous studies has been applied to different cardiovascular traits (51) . Although still under development (51), the use of genetic risk scores to predict cardiovascular outcomes and intermediate traits or subclinical phenotypes, including coronary heart/artery disease (52), MI (53), ischemic stroke (54), or hypertension (55), has been successful.
This study was powered to detect an association with an effect size of 0.1 at an alpha level of 0.05. However, the observed effect sizes were much lower, if not negligible. For example, if we sought to detect an association of 0.5% (that could be considered clearly insignificant), we would need a sample size of 1,731. Moreover, the positive association with the ABO SNP supports the notion that this study was sufficiently powered to detect associations of CAD-related SNPs with susceptibility if they were present. Therefore, it is appropriate to infer that the CAD-related SNPs are unlikely to be a significant source of variability for CAC in RA patients. The ABO locus encodes glycotransferases that, when absent in individuals with blood group O, protect against MI (24), although their relationship to CAC in RA patients suggests that they may foster CAC development in this setting by mechanisms that differ from those in individuals without RA.
The interpretation that factors intrinsic to RA independently contribute to CAC is supported by the finding that CAC is clearly related to disease activity as shown by the DAS28. Indeed, the increased DAS28 in those with higher CAC scores remained significant even after adjustment for traditional cardiovascular risk factors, as well as adjustment for the genetic risk scores for alleles influencing CAD in the general population.
Similarly, one immunologic mechanism in RA that is not related to CAD-associated SNPs, which could potentially contribute to the association, is the finding that CAC in RA patients is significantly and independently associated with an elevated percentage of circulating CD28-CD571CD561 memory effector CD4 T cells and with an increased proportion of the CD14 high CD161 monocyte subset bearing an intermediate or "inflammatory" phenotype (56) . These increased numbers of memory effector T cell and inflammatory monocyte subsets, which are considered an intrinsic element in the immune response mediating RA, may also provide the nascent and clinically unimportant subintimal lipid deposits with effector T cells and inflammatory monocytes that could accelerate the development of advanced atherosclerotic vascular disease.
Additionally, several studies (57) support the association between CVD and polymorphic genes involved in influencing RA susceptibility or the severity of effector pathways of RA. These include the association of alleles encoding the HLA-DR shared epitope with both subclinical and clinically evident CVD (58) , and the association of variants belonging to genes implicated in inflammatory and metabolic pathways, such as rs1800629 (TNFA), rs909253 (LTA), rs1800795 (IL6), rs333 (CCR5), rs2812378 (CCL21), and rs1800470 (TGFB1), with increased risk of endothelial dysfunction, different types of cardiovascular events, and cardiovascular mortality in RA (57, (59) (60) (61) (62) .
This study has some limitations. First, it should be considered exploratory, because the experimental design does not include a validation cohort. Second, although genotyping was facilitated in our study because a considerable proportion of CAD-related SNPs were fortuitously present on the Immunochip, the studies exploring susceptibility to CAD in the general population used different chips (most notably the Metabolic chip), each of which has a different spectrum of SNPs. Therefore, we had to use imputation, which is still an evolving approach, to identify some important polymorphisms (43) . Third, CAC appears at an intermediate stage in the development of atherosclerosis, and the assessment of earlier stages of atherosclerosis may prove more sensitive, as would adding the later stage of a myocardial event. Fourth, the association observed between the DAS28 and CAC could be influenced by noninflammatory comorbidities (e.g., depression, fibromyalgia, osteoarthritis) that can also lead to a higher DAS28.
The role of genetic factors in accelerated CVD in RA requires further study to better identify the mechanisms 538 FERRAZ-AMARO ET AL and pathways responsible for this association. To our knowledge, this is the first investigation in which CADrelated SNPs in the general population have been assessed in a large set of RA patients, with a reproducible, sensitive, quantitative measure of CAD. Our finding of the absence of an association of these CAD-related SNPs with CAC in patients with RA is novel and could shed light on the complicated relationship between inflammation and cardiovascular risk in RA.
In conclusion, we have shown that even when all known genetic susceptibility variants associated with CAD in the general population were included in the analysis, the gene dosage of these susceptible CADrelated SNPs was not associated with the increased incidence of CAC observed in RA patients. Our findings support the role of one or more mechanistic features in RA itself as the fundamental factor responsible for the increased incidence of CVD in patients with RA.
